# A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

> **NCT03763318** · PHASE1,PHASE2 · COMPLETED · sponsor: **Equillium** · enrollment: 30 (actual)

## Conditions studied

- Acute-graft-versus-host Disease
- aGVHD
- GVHD
- GVHD, Acute

## Interventions

- **BIOLOGICAL:** EQ001
- **BIOLOGICAL:** EQ001 Placebo

## Key facts

- **NCT ID:** NCT03763318
- **Lead sponsor:** Equillium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-15
- **Primary completion:** 2022-11-21
- **Final completion:** 2022-11-21
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763318, "A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03763318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*